Medipal Holdings
VC Fund
Tokyo, Japan
Medipal Holdings is a holding company that engages in the sale of pharmaceuticals, cosmetics, and daily necessities. The company is founded on October 8, 1898, and is headquartered in Tokyo, Japan.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Medipal Holdings invests in
Stages Medipal Holdings invests in
Countries Medipal Holdings invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Toshihide Yoda
|
|||
|
Kazuo Hashida
|
|||
Shuichi Watanabe
|
|||
Investment Focus
Industry
- Health Care 4 (57%)
- Medical 2 (29%)
- Biotechnology 2 (29%)
- Medical Device 2 (29%)
- Beauty 1 (14%)
Stage
- Corporate Round 3 (43%)
- Series B 1 (14%)
- Series C 1 (14%)
- Funding Round 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Toshihide Yoda
Director
|
Director | Total investments: 1 | Find email | |
|
Kazuo Hashida
Executive Officer, Director of Finance & Accounting
|
Executive Officer, Director of Finance & Accounting | Total investments: 0 | Find email | |
|
Shuichi Watanabe
Representative Director, President and CEO
|
Representative Director, President and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
N.B.Medical
|
N.B.Medical is a medical equipment manufacturer that specializes in the development of next-generation neurovascular devices and in-silico regulatory technologies. The compant integrates real-world medical device development with regulation-integrated CMS and AI-driven digital-twin technologies to establish a proprietary development model. | $13.7M / Series B / Aug 30, 2024 | |
Heartseed
|
Heartseed is a biotechnology research firm that specializes in the development of purified ventricular cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure. The company employs an innovative methodology that involves the creation of cardiomyocyte spheroids, small clusters of heart cells, using stem cells.These spheroids are then surgically implanted into the heart to improve its performance. | $37M / Series C / Jun 11, 2021 | |
|
Heartseed
|
Heartseed is a biotechnology research firm that specializes in the development of purified ventricular cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure. The company employs an innovative methodology that involves the creation of cardiomyocyte spheroids, small clusters of heart cells, using stem cells.These spheroids are then surgically implanted into the heart to improve its performance. | $955.3K / Corporate Round / Mar 10, 2020 | |
CLIPLA
|
CLIPLA recognizes the importance of protecting personal information and the social nature of medical-related businesses. | $66.6M / Corporate Round / Mar 13, 2018 | |
Scohia Pharma
|
Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $1.4B / Corporate Round / Mar 14, 2017 | |
FunPep
|
FunPep is an Industry-university collaboration bioventure company. | $35.4M / Apr 14, 2016 | |
|
FunPep
|
FunPep is an Industry-university collaboration bioventure company. |
Co-Investors
ITOCHU Chemical Frontier
2 deals together
Bio-sight Capital
1 deal together
Dainippon Sumitomo Pharma
1 deal together
FANCL
1 deal together
Innovation Network Corporation of Japan
1 deal together
Keio Innovation Initiative
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Medipal Holdings invest in?
Medipal Holdings invests primarily in Health Care, Medical and Biotechnology startups, most often at Corporate Round and Series B stage. Most of the 7 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Medipal Holdings?
Public channels for Medipal Holdings include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Medipal Holdings?
The team at Medipal Holdings includes Toshihide Yoda (Director), Kazuo Hashida (Executive Officer, Director of Finance & Accounting) and Shuichi Watanabe (Representative Director, President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
